Application of percutaneous ultrasound-guided treatment for ultrasonically invisible hypervascular hepatocellular carcinoma using microbubble contrast agent

Clinical Radiology

Volumn 62, Issue 7, 2007, Pages 668-675

  Maruyama, H ^a   Kobayashi, S ^a   Yoshizumi, H ^a   Okugawa, H ^a   Akiike, T ^a   Yukisawa, S ^a   Fukuda, H ^a   Matsutani, S ^a   Ebara, M ^a   Saisho, H ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

SHU 508;

ADULT; AGED; ARTICLE; CANCER LOCALIZATION; CHEMOEMBOLIZATION; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DISEASE ACTIVITY; ECHOGRAPHY; FALSE POSITIVE RESULT; FEMALE; FOLLOW UP; HUMAN; INTERMETHOD COMPARISON; LIVER CELL CARCINOMA; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; MICROBUBBLE; NEEDLE BIOPSY; PRIORITY JOURNAL; SINGLE DRUG DOSE; THERAPY EFFECT; TREATMENT OUTCOME; TUMOR VASCULARIZATION; TUMOR VOLUME;

AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; CONTRAST MEDIA; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; POLYSACCHARIDES; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 34249681922     PISSN: 00099260     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.crad.2006.11.025     Document Type: Article

References (57)

1. Okuda K. Hepatocellular carcinoma: recent progress. Hepatology 15 (1992) 948-963
2. Okuda K. Hepatocellular carcinoma. J Hepatol 32 (2000) S225-S237
3. Bruix J., Sherman M., Llovet J., et al. EASL panel of experts on HCC. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona 2000 EASL conference. J Hepatol 35 (2001) 421-430
4. Nino-Murcia M., Olcott E.W., Jeffrey Jr. R.B., et al. Focal liver lesions: pattern-based classification scheme for enhancement at arterial phase CT. Radiology 215 (2000) 746-751
5. Ebara M., Ohto M., Sugiura N., et al. Percutaneous ethanol injection for the treatment of small hepatocellular carcinoma. Study of 95 patients. J Gastroenterol Hepatol 5 (1990) 616-626
6. Livraghi T., Bolondi L., Lazzaroni S., et al. Percutaneous ethanol injection in the treatment of hepatocellular carcinoma in cirrhosis. A study on 207 patients. Cancer 69 (1992) 925-929
7. Lencioni R., Bartolozzi C., Caramella D., et al. Treatment of small hepatocellular carcinoma with percutaneous ethanol injection: analysis of prognostic factors in 105 Western patients. Cancer 76 (1995) 1737-1746
8. Goldberg S.N., Gazelle G.S., Solbiati L., et al. Radiofrequency tissue ablation: increased lesion diameter with a perfusion electrode. Acad Radiol 3 (1996) 636-644
9. Solbiati L., Goldberg S.N., Ierace T., et al. Hepatic metastases: percutaneous radio-frequency ablation with cooled-tip electrodes. Radiology 205 (1997) 367-373
10. Ryu M., Shimamura Y., Kinoshita T., et al. Therapeutic results of resection, transcatheter arterial embolization and percutaneous ethanol injection in 3225 patients with hepatocellular carcinoma: a retrospective multicenter study. Jpn J Clin Oncol 27 (1997) 251-257
11. Ebara M., Okabe S., Kita K., et al. Percutaneous ethanol injection for small hepatocellular carcinoma: therapeutic efficacy based on 20-year observation. J Hepatol 43 (2005) 458-464
12. Takayasu K., Muramatsu Y., Asai S., et al. CT fluoroscopy-assisted needle puncture and ethanol injection for hepatocellular carcinoma: a preliminary study. AJR Am J Roentgenol 173 (1999) 1219-1224
13. Sato M., Watanabe Y., Tokui K., et al. CT-guided treatment of ultrasonically invisible hepatocellular carcinoma. Am J Gastroenterol 95 (2000) 2102-2106
14. Schweiger G.D., Brown B.P., Pelsang R.E., et al. CT fluoroscopy: technique and utility in guiding biopsies of transiently enhancing hepatic masses. Abdom Imaging 25 (2000) 81-85
15. Shibata T., Iimuro Y., Yamamoto Y., et al. CT-guided transthoracic percutaneous ethanol injection for hepatocellular carcinoma not detected with US. Radiology 223 (2002) 115-120
16. Kirchner J., Kickuth R., Laufer U., et al. CT fluoroscopy-assisted puncture of thoracic and abdominal masses: a randomized trial. Clin Radiol 57 (2002) 188-192
17. Solomon S.B., Bohlman M.E., and Choti M.A. Percutaneous gadolinium injection under MR guidance to mark target for CT-guided radiofrequency ablation. J Vasc Interv Radiol 13 (2002) 419-421
18. Adam A., Hatzidakis A., Hamady M., et al. Percutaneous coil placement prior to radiofrequency ablation of poorly visible hepatic tumors. Eur Radiol 14 (2004) 1688-1691
19. Bartolozzi C., Lencioni R., Ricci P., et al. Hepatocellular carcinoma treatment with percutaneous ethanol injection: evaluation with contrast-enhanced color Doppler US. Radiology 209 (1998) 387-393
20. Solbiati L., Goldberg S.N., Ierace T., et al. Radio-frequency ablation of hepatic metastases: postprocedural assessment with a US microbubble contrast agent-early experience. Radiology 211 (1999) 643-649
21. Blomley M.J., Albrecht T., Cosgrove D.O., et al. Improved imaging of liver metastases with stimulated acoustic emission in the late phase of enhancement with the US contrast agent SHU 508A: early experience. Radiology 210 (1999) 409-416
22. Harvey C.J., Blomley M.J., Eckersley R.J., et al. Pulse-inversion mode imaging of liver specific microbubbles: improved detection of subcentimetre metastases. Lancet 355 (2000) 807-808
23. Harvey C.J., Blomley M.J., Eckersley R.J., et al. Hepatic malignancies: improved detection with pulse-inversion US in late phase of enhancement with SHU 508A-early experience. Radiology 216 (2000) 903-908
24. Kim T.K., Choi B.I., Hong H.S., et al. Improved imaging of hepatic metastases with delayed pulse inversion harmonic imaging using a contrast agent SHU 508A: preliminary study. Ultrasound Med Biol 26 (2000) 1439-1444
25. Choi D., Lim H.K., Kim S.H., et al. Hepatocellular carcinoma treated with percutaneous radio-frequency ablation: usefulness of power Doppler US with a microbubble contrast agent in evaluating therapeutic response-preliminary results. Radiology 217 (2000) 558-563
26. Kim T.K., Choi B.I., Han J.K., et al. Hepatic tumors: contrast agent-enhancement patterns with pulse-inversion harmonic US. Radiology 216 (2000) 411-417
27. Meloni M.F., Goldberg S.N., Livraghi T., et al. Hepatocellular carcinoma treated with radiofrequency ablation: comparison of pulse inversion contrast-enhanced harmonic sonography, contrast-enhanced power Doppler sonography, and helical CT. AJR Am J Roentgenol 177 (2001) 375-380
28. von Herbay A., Vogt C., and Haussinger D. Pulse inversion sonography in the early phase of the sonographic contrast agent Levovist: differentiation between benign and malignant focal liver lesions. J Ultrasound Med 21 (2002) 1191-1200
29. Wen Y.L., Kudo M., Zheng R.Q., et al. Radiofrequency ablation of hepatocellular carcinoma: therapeutic response using contrast-enhanced coded phase-inversion harmonic sonography. AJR Am J Roentgenol 181 (2003) 57-63
30. Morimoto M., Shirato K., Sugimori K., et al. Contrast-enhanced harmonic gray-scale sonographic-histologic correlation of the therapeutic effects of transcatheter arterial chemoembolization in patients with hepatocellular carcinoma. AJR Am J Roentgenol 181 (2003) 65-69
31. von Herbay A., Vogt C., and Haussinger D. Differentiation between benign and malignant hepatic lesions: utility of color stimulated acoustic emission with the microbubble contrast agent Levovist. J Ultrasound Med 23 (2004) 207-215
32. Bryant T.H., Blomley M.J., Albrecht T., et al. Improved characterization of liver lesions with liver-phase uptake of liver-specific microbubbles: prospective multicenter study. Radiology 232 (2004) 799-809
33. Dietrich C.F., Ignee A., Trojan J., et al. Improved characterization of histologically proven liver tumours by contrast enhanced ultrasonography during the portal venous and specific late phase of SHU 508A. Gut 53 (2004) 401-405
34. Kim C.K., Choi D., Lim H.K., et al. Therapeutic response assessment of percutaneous radio frequency ablation for hepatocellular carcinoma: utility of contrast-enhanced agent detection imaging. Eur J Radiol 56 (2005) 66-73
35. Maruyama H., Matsutani S., Okugawa H., et al. Microbubble disappearance-time is the appropriate timing for liver-specific imaging after injection of Levovist. Ultrasound Med Biol 32 (2006) 1809-1815
36. Joseph A.E., Saverymuttu S.H., Al-Sam S., et al. Comparison of liver histology with ultrasonography in assessing diffuse parenchymal liver disease. Clin Radiol 43 (1991) 26-31
37. Kitamura S., Iishi H., Tatsuta M., et al. Liver with hypoechoic nodular pattern as a risk factor for hepatocellular carcinoma. Gastroenterology 108 (1995) 1778-1784
38. Tarao K., Hoshino H., Shimizu A., et al. Patients with ultrasonic coarse-nodular cirrhosis who are anti-hepatitis C virus-positive are at high risk for hepatocellular carcinoma. Cancer 75 (1995) 1255-1262
39. Shapiro R.S., Wagreich J., Parsons R.B., et al. Tissue harmonic imaging sonography: evaluation of image quality compared with conventional sonography. AJR Am J Roentgenol 171 (1998) 1203-1206
40. Hann L.E., Bach A.M., Cramer L.D., et al. Hepatic sonography: comparison between tissue harmonic and standard sonography techniques. AJR Am J Roentgenol 173 (1999) 201-206
41. Whittingham T.A. Tissue harmonic imaging. Eur Radiol 9 (1999) S323-S326
42. Harvey C.J., and Albrecht T. Ultrasound of focal lesions. Eur Radiol 11 (2001) 1578-1593
43. Numata K., Isozaki T., Ozawa Y., et al. Percutaneous ablation therapy guided by contrast-enhanced sonography for patients with hepatocellular carcinoma. AJR Am J Roentgenol 180 (2003) 143-149
44. Yu J.S., Kim K.W., Sung K.B., et al. Small arterial-portal venous shunts: cause of pseudolesions at hepatic imaging. Radiology 203 (1997) 737-742
45. Kim T.K., Choi B.I., Han J.K., et al. Nontumorous arterioportal shunt mimicking hypervascular tumor in cirrhotic liver: two-phase spiral CT findings. Radiology 208 (1998) 597-603
46. Brancatelli G., Baron R.L., Peterson M.S., et al. Helical CT screening for hepatocellular carcinoma in patients with cirrhosis: frequency and causes of false-positive interpretation. AJR Am J Roentgenol 180 (2003) 1007-1014
47. Kudo M. Imaging diagnosis of hepatocellular carcinoma and premalignant/borderline lesions. Semin Liver Dis 19 (1999) 297-309
48. Hayashi M., Matsui O., Ueda K., et al. Progression to hypervascular hepatocellular carcinoma: correlation with intranodular blood supply evaluated with CT during intraarterial injection of contrast material. Radiology 225 (2002) 143-149
49. Bolondi L., Gaiani S., Celli N., et al. Characterization of small nodules in cirrhosis by assessment of vascularity: the problem of hypovascular hepatocellular carcinoma. Hepatology 42 (2005) 27-34
50. Bruix J., and Sherman M. Practice Guidelines Committee, American Association for the study of liver diseases. Management of hepatocellular carcinoma. Hepatology 42 (2005) 1208-1236
51. Roncalli M., Roz E., Coggi G., et al. The vascular profile of regenerative and dysplastic nodules of the cirrhotic liver: implication for diagnosis and classification. Hepatology 30 (1999) 1174-1178
52. International Working Party. Terminology of nodular hepatocellular lesions. Hepatology 22 (1995) 983-989
53. Borzio M., Fargion S., Borzio F., et al. Impact of large regenerative, low grade and high grade dysplastic nodules in hepatocellular carcinoma development. J Hepatol 39 (2003) 208-214
54. Tanaka M., Nakashima O., Wada Y., et al. Pathomorphological study of Kupffer cells in hepatocellular carcinoma and hyperplastic nodular lesions in the liver. Hepatology 24 (1996) 807-812
55. Lim J.H., Choi D., Cho S.K., et al. Conspicuity of hepatocellular nodular lesions in cirrhotic livers at ferumoxides-enhanced MR imaging: Importance of Kupffer cell number. Radiology 220 (2001) 669-676
56. Krix M., Kiessling F., Essig M., et al. Low mechanical index contrast-enhanced ultrasound better reflects high arterial perfusion of liver metastases than arterial phase computed tomography. Invest Radiol 39 (2004) 216-222
57. Maruyama H., Matsutani S., Saisho H., et al. Real-time blood-pool images of contrast enhanced ultrasound with Definity in the detection of liver tumour nodules in the liver. Br J Radiol 78 (2005) 512-518